ADC (ANTIBODY-DRUG CONJUGATES)
An Antibody-Drug Conjugate (ADC) is a powerful form of targeted cancer therapy that combines the specificity of monoclonal antibodies with the cell-killing ability of potent cytotoxic drugs.
Structurally, an ADC consists of three main components: an antibody that precisely targets a specific antigen found mainly on cancer cells, a chemical linker that connects the antibody to the drug, and a highly toxic payload designed to kill cancer cells upon delivery.
Allianz Bio, in collaboration with ACRO Biosystems, provides comprehensive support across the entire antibody-drug conjugate (ADC) development pipeline. This includes Discovery & Development, CMC-Manufacturing, CMC-Quality Control, Preclinical Studies, and Clinical Studies—ensuring high-quality, end-to-end solutions for ADC projects.
Key Features
- Targeted Cancer Therapy Combines antibody specificity with potent cytotoxic drug delivery.
- Three-Part Structure Includes a targeting antibody, stable linker, and toxic payload for precise tumor cell killing.
- Full ADC Development Support End-to-end services from discovery to clinical stages.
- CMC & Quality Control Expertise Support for manufacturing and regulatory-compliant quality assessment.
- Collaborative Platform Powered by Allianz Bio and ACRO Biosystems for integrated ADC development solutions.
